Cameron Bissett
A5043691113- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Animal Virus Infections Studies
- vaccines and immunoinformatics approaches
- Respiratory viral infections research
- Immune responses and vaccinations
- Viral Infections and Immunology Research
- Viral gastroenteritis research and epidemiology
- Cancer Immunotherapy and Biomarkers
- Vaccine Coverage and Hesitancy
- Retinal and Optic Conditions
- SARS-CoV-2 detection and testing
- Immunotherapy and Immune Responses
- Influenza Virus Research Studies
University of Oxford
2020-2024
Jenner Institute
2020-2022
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 20191,2 and is responsible for the disease 2019 (COVID-19) pandemic3. Vaccines are an essential countermeasure urgently needed to control pandemic4. Here we show that adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which encodes spike protein of SARS-CoV-2, immunogenic mice elicites a robust humoral cell-mediated response. This response was predominantly mediated by type-1 T helper cells, as demonstrated...
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in December 2019 1,2 and is responsible for the COVID-19 pandemic 3 . Vaccines are an essential countermeasure urgently needed to control 4 Here, we show that adenovirus-vectored vaccine ChAdOx1 nCoV-19, encoding spike protein of SARS-CoV-2, immunogenic mice, eliciting a robust humoral cell-mediated response. This response was not Th2 dominated, as demonstrated by IgG subclass cytokine expression profiling. A single...
SummaryBackgroundCOVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between first and second dose becomes longer. Conversely, with no constraints considering administering a third dose. We assessed persistence of immunogenicity after single ChAdOx1 nCoV-19 (AZD1222), an extended (44–45 weeks) dose, response to booster given 28–38 weeks dose.MethodsIn this substudy, volunteers aged 18–55 years who were enrolled phase 1/2...
Abstract Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet there is limited data on the immune response induced by heterologous vaccination regimens using alternate vaccine modalities. Here, we present a detailed description of response, in mice, following with self-amplifying RNA (saRNA) and an adenoviral vectored (ChAdOx1 nCoV-19/AZD1222) SARS-CoV-2. We demonstrate that antibody responses are higher two-dose than single-dose regimens. Neutralising titres...
A Correction to this paper has been published: https://doi.org/10.1038/s41586-020-03099-2
Abstract Although licensed vaccines against influenza virus have been successful in reducing pathogen-mediated disease, they less effective at preventing viral infection of the airways and current seasonal updates to do not always successfully accommodate drift. Most recently RSV are administered via intramuscular route. Alternative immunisation strategies, such as intranasal vaccinations, “prime-pull” regimens, may deliver a more sterilising form protection respiratory viruses. A bivalent...
Abstract There is an ongoing global effort to design, manufacture, and clinically assess vaccines against SARS-CoV-2. Over the course of pandemic a number new SARS-CoV-2 virus isolates or variants concern (VoC) have been identified containing mutations in key proteins. In this study we describe generation preclinical assessment ChAdOx1-vectored vaccine (AZD2816) which expresses spike protein Beta VoC (B.1.351). We demonstrate that AZD2816 immunogenic after single dose. When used as booster...
Abstract Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet there is limited data on the immune response induced by heterologous vaccination regimens using alternate vaccine modalities. Here, we present a detailed description of response, in mice, following with self-amplifying RNA (saRNA) and an adenoviral vectored (ChAdOx1 nCoV-19/AZD1222) SARS-CoV-2. We demonstrate that antibody responses are higher two dose than single regimens. Neutralising titres after...